Skip to main
HOWL
HOWL logo

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics Inc demonstrates a strong outlook due to its innovative PREDATOR platform, which enables the development of therapeutics that precisely activate immunity within the tumor microenvironment, addressing critical gaps in existing cancer treatments. The company's strategic advancements and proprietary technology foster confidence in its potential to deliver groundbreaking therapies, thereby appealing to investors interested in the biopharmaceutical sector. Additionally, Werewolf's focus on conditionally activated INDUKINE molecules highlights its commitment to enhancing therapeutic efficacy while minimizing off-target effects, indicating a strong foundation for future revenue growth and market differentiation.

Bears say

Werewolf Therapeutics is facing a challenging financial outlook as reflected in the weak performance metrics. Specifically, the company experienced a revenue decline of 30 basis points year-over-year, coupled with a significant 3.8% increase in expenses, leading to a net operating income (NOI) decline of 2.6%. Additionally, the average effective rental rate decreased by 50 basis points year-over-year, driven by a substantial drop in new lease rates, which raises concerns about the company’s ability to generate sufficient revenue moving forward.

Werewolf Therapeutics (HOWL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 4 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.